Other languages Iconovo AB

Equities

ICO

SE0010868943

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
8.7 ^SEK	+0.23%		-4.40%	-24.68%

May. 15	Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	CI
May. 06	Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	May. 15
Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	May. 06
Iconovo AB Receives Patent Protection for Icores in China	May. 06
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	Mar. 11
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	Feb. 07
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	Feb. 06
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	Feb. 01
Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD	Nov. 16
Iconovo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27
Iconovo AB Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone	23-09-26
Iconovo AB Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations	23-09-19
Iconovo AB Launches Outreach Phase in Structured Process for Out-Licensing of ICOpre	23-09-13
Iconovo AB Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027	23-08-23
Iconovo to Launch Pharmacokinetic Study for Inhalable Treatment Under Kiox Pharma Partnership	23-08-17
Iconovo AB Receives Additional Development Contract from Kiox Pharma for New Inhalable Treatment Against Rare Disease	23-08-17
Iconovo AB, Provides Earnings Guidance for 2024 and 2025	23-08-16
Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Iconovo AB

Equities

ICO

SE0010868943

Other languages

Filters